Strategies Based on Evidence to Rationalize the High Cost Drugs National List in the Dominican Republic

Strategies Based on Evidence to Rationalize the High Cost Drugs National List in the Dominican Republic

By: E. Barillas, C. Valdez, E. Narvaez, G. Vasquez
Publication: Value in HealthNov. 2015; 8 (7): A657. DOI: 10.1016/j.jval.2015.09.2376.

Abstract

In 2014, the budget for high cost drugs in the Dominican Republic was USD 107 million, accounting for 51% of the Ministry of Health (MoH) budget for medicines. Resources allocated for the 2015 budget were USD 49 million, leaving a shortfall of USD 62 million. The MoH requested technical assistance from the USAID-funded SIAPS project to conduct an evidence based analysis of the 98 products included in the list.